Strategic Funding Epitel has secured a $26M Series B and received grant funding from the Department of Health and Human Services, signaling validated market potential and investor confidence. This momentum can be leveraged to open discussions with payers, health systems, and government-funded programs for expanded deployment.

Remote Monitoring Growth Recent financing and press emphasize expansion of remote wireless EEG monitoring capabilities. Sales outreach should target clinics, hospitals, and telehealth platforms seeking scalable, non-invasive brain health solutions to extend monitoring reach and improve seizure detection.

AI driven Differentiation Epitel positions itself as an AI-driven wireless brain health technology provider with REMI platform development. Potential upsell opportunities exist with hospitals and IDNs looking to integrate AI insights into seizure management workflows and decision support tools.

Strategic Partnerships Recent Stratus partnership expands EEG access, indicating a favorable collaboration track. Explore co-sales or integration opportunities with Stratus and similar distributors or service providers to broaden market access and install base.

Executive Leadership New CEO Steve Pacelli appointment alongside strong investor backing suggests a growth-oriented strategy. Engage proactively with leadership to align on procurement cycles, pilot programs, and reference deployments to accelerate adoption.